Chong Wei

机构：Northwestern Polytechnical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, San Francisco Bay University · ORCID：0000-0001-9690-8555

发表论文 96 篇 · 总被引 458 次 · h-index 10

代表论文

• Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma (2025 · JAMA Dermatology · 被引 8)
• Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma (2024 · Frontiers in Immunology · 被引 6)
• Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases (2025 · Annals of Hematology · 被引 4)
• Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study (2025 · Oncology · 被引 1)
• Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial (2025 · Blood · 被引 1)
• Clinical outcome and immunophenotype of axicabtagene ciloleucel (axi-cel) and relmacabtagene autoleucel (relma-cel) in relapsed/refractory large B-Cell lymphoma on Chinese population: a single-center experience (2025 · Annals of Hematology · 被引 1)